Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Apr 3

PMID 33800900

Citations 7

Authors

Andreia Gameiro

Filipe Almeida

Catarina Nascimento

Jorge Correia

Fernando Ferreira

Affiliations

Soon will be listed here.

Abstract

Feline mammary carcinoma (FMC) is a common neoplasia in cat, being HER2-positive the most prevalent subtype. In woman's breast cancer, tyrosine kinase inhibitors (TKi) are used as a therapeutic option, by blocking the phosphorylation of the HER2 tyrosine kinase domain. Moreover, clinical trials demonstrated that TKi produce synergistic antiproliferative effects in combination with mTOR inhibitors, overcoming resistance to therapy. Thus, to uncover new chemotherapeutic strategies for cats, the antiproliferative effects of two TKi (lapatinib and neratinib), and their combination with a mTOR inhibitor (rapamycin), were evaluated in FMC cell lines (CAT-M, FMCp and FMCm) and compared with a human breast cancer cell line (SkBR-3). Results revealed that both TKi induced antiproliferative effects in all feline cell lines, by blocking the phosphorylation of EGFR members and its downstream effectors. Furthermore, combined treatments with rapamycin presented synergetic antiproliferative effects. Additionally, the DNA sequence of the TK domain (exons 18 to 20) was determined in 40 FMC tissue samples, and despite several mutations were found none of them were described as inducing resistance to therapy. Altogether, our results demonstrated that TKi and combined protocols may be useful in the treatment of cats with mammary carcinomas, and that TKi-resistant FMC are rare.

Citing Articles

The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies.

Guo H, Xu X, Zhang J, Du Y, Yang X, He Z Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204153 PMC: 11357454. DOI: 10.3390/ph17081048.

Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.

Aupperle-Lellbach H, Kehl A, de Brot S, van der Weyden L Vet Sci. 2024; 11(5).

PMID: 38787171 PMC: 11126050. DOI: 10.3390/vetsci11050199.

Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration.

Yu T, Yamamoto H, Morita S, Fukushima R, Elbadawy M, Usui T J Vet Med Sci. 2024; 86(3):317-321.

PMID: 38281758 PMC: 10963087. DOI: 10.1292/jvms.23-0448.

A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions.

Zagar Z, Schmidt J Animals (Basel). 2023; 13(19).

PMID: 37835664 PMC: 10572079. DOI: 10.3390/ani13193059.

Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma.

Gameiro A, Urbano A, Ferreira F Vet Sci. 2021; 8(8).

PMID: 34437486 PMC: 8402877. DOI: 10.3390/vetsci8080164.

References

Garczyk S, Klotz N, Szczepanski S, Denecke B, Antonopoulos W, von Stillfried S . Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway. Oncotarget. 2017; 8(22):36246-36265. PMC: 5482652. DOI: 10.18632/oncotarget.16121. View

Canfield K, Li J, Wilkins O, Morrison M, Ung M, Wells W . Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle. 2015; 14(4):648-55. PMC: 4614407. DOI: 10.4161/15384101.2014.994966. View

Zhao X, Xie J, Chen X, Sim H, Zhang X, Liang Y . Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. Mol Pharmacol. 2012; 82(1):47-58. PMC: 3382829. DOI: 10.1124/mol.111.076299. View

Hanker A, Brewer M, Sheehan J, Koch J, Sliwoski G, Nagy R . An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discov. 2017; 7(6):575-585. PMC: 5457707. DOI: 10.1158/2159-8290.CD-16-1431. View

Scaltriti M, Verma C, Guzman M, Jimenez J, Parra J, Pedersen K . Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2008; 28(6):803-14. DOI: 10.1038/onc.2008.432. View

Watanabe R, Wei L, Huang J . mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med. 2011; 52(4):497-500. DOI: 10.2967/jnumed.111.089623. View

Diederichs S, Bartsch L, Berkmann J, Frose K, Heitmann J, Hoppe C . The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. EMBO Mol Med. 2016; 8(5):442-57. PMC: 5126213. DOI: 10.15252/emmm.201506055. View

Maccario H, Perera N, Davidson L, Downes C, Leslie N . PTEN is destabilized by phosphorylation on Thr366. Biochem J. 2007; 405(3):439-44. PMC: 2267318. DOI: 10.1042/BJ20061837. View

Appert-Collin A, Hubert P, Cremel G, Bennasroune A . Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol. 2015; 6:283. PMC: 4657385. DOI: 10.3389/fphar.2015.00283. View

10.

Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M . Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009; 153(1):13-7. DOI: 10.5507/bp.2009.002. View

11.

Chen Y, Yeh M, Yu M, Wei Y, Chen W, Chen J . Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. Breast Cancer Res. 2013; 15(6):R108. PMC: 3979035. DOI: 10.1186/bcr3575. View

12.

Hoberg-Vetti H, Ognedal E, Buisson A, Vamre T, Ariansen S, Hoover J . The intronic BRCA1 c.5407-25T>A variant causing partly skipping of exon 23-a likely pathogenic variant with reduced penetrance?. Eur J Hum Genet. 2020; 28(8):1078-1086. PMC: 7382492. DOI: 10.1038/s41431-020-0612-1. View

13.

McGowan P, Mullooly M, Caiazza F, Sukor S, Madden S, Maguire A . ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann Oncol. 2012; 24(2):362-369. DOI: 10.1093/annonc/mds279. View

14.

Jhanwar-Uniyal M, Wainwright J, Mohan A, Tobias M, Murali R, Gandhi C . Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Adv Biol Regul. 2019; 72:51-62. DOI: 10.1016/j.jbior.2019.03.003. View

15.

Shi H, Zhang W, Zhi Q, Jiang M . Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms. Tumour Biol. 2016; 37:15411–15431. DOI: 10.1007/s13277-016-5467-2. View

16.

Ferreira D, Soares M, Correia J, Adega F, Ferreira F, Chaves R . Assessment of and gene status and expression profile in feline mammary tumors: findings and guidelines. Aging (Albany NY). 2019; 11(13):4688-4705. PMC: 6660035. DOI: 10.18632/aging.102079. View

17.

Sun Z, Shi Y, Shen Y, Cao L, Zhang W, Guan X . Analysis of different HER-2 mutations in breast cancer progression and drug resistance. J Cell Mol Med. 2015; 19(12):2691-701. PMC: 4687700. DOI: 10.1111/jcmm.12662. View

18.

Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S . Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors. Cancer Res. 2014; 74(14):3821-33. DOI: 10.1158/0008-5472.CAN-13-2053. View

19.

Anczukow O, Buisson M, Leone M, Coutanson C, Lasset C, Calender A . BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy. Clin Cancer Res. 2012; 18(18):4903-9. DOI: 10.1158/1078-0432.CCR-12-1100. View

20.

Vail D, MacEwen E . Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000; 18(8):781-92. DOI: 10.3109/07357900009012210. View